| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | UNI HEALTH (02211): REVISED FORM OF PROXY FOR USE AT EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| UNIVERSAL HEALTH INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 27.08. | UNI HEALTH (02211): FORM OF PROXY FOR USE AT EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 27.08. | UNI HEALTH (02211): NOTICE OF EGM | 1 | HKEx | ||
| 27.08. | UNI HEALTH (02211): PROPOSED CAPITAL REORGANISATION; PROPOSED RIGHTS ISSUE ON THE BASIS OF FOUR (4) RIGHTS SHARES FOR EVERY ONE (1) ADJUSTED SHARE HELD ... | 1 | HKEx | ||
| 31.07. | UNI HEALTH (02211): DELAY IN DESPATCH OF CIRCULAR AND REVISED TIMETABLE IN RELATION TO PROPOSED CAPITAL REORGANISATION AND RIGHTS ISSUE | 1 | HKEx | ||
| 17.07. | UNI HEALTH (02211): (I) PROPOSED CAPITAL REORGANISATION; AND (II) PROPOSED RIGHTS ISSUE ON THE BASIS OF FOUR (4) RIGHTS SHARES FOR EVERY ONE (1) ADJUSTED ... | - | HKEx | ||
| 27.03. | UNI HEALTH (02211): 2025/2026 INTERIM REPORT | 2 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 49,100 | -0,63 % | Gute Nachrichten von Zefiro Methane, Bayer und Disney: Drei interessante Aktien im News-Check | Erstellt und veröffentlicht im Auftrag von Zefiro Methane An der Börse führen viele Wege zum Erfolg. Zefiro Methane profitiert von der Sanierung alter Öl- und Gasquellen in Nordamerika, Bayer arbeitet... ► Artikel lesen | |
| AURORA CANNABIS | 3,262 | -1,92 % | Curaleaf Holdings, Inc.: Curaleaf Responds to Aurora Cannabis Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders | Highlights
Curaleaf Offers a 45% Premium and Meaningful Future Upside: Aurora shareholders can realize immediate value alongside the opportunity to participate... ► Artikel lesen | |
| MPH HEALTH CARE | 26,500 | +1,14 % | Dividendenbekanntmachungen (10.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCE AUTO PARTS INC US00751Y1064 0,25 USD 0,2187 EUR ALPHA BANK SA ADR US02071M5076 0,0187 USD 0,0163 EUR AMERICAN EAGLE OUTFITTERS... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,560 | -2,38 % | Green Thumb Industries Has Hit a Rough Patch. Here's Why Its Best Days Could Be Ahead. | ||
| ATRIUM THERAPEUTICS | 11,350 | 0,00 % | Atrium Therapeutics auf Wells-Fargo-Konferenz: RNA-Vorstoß bei Herzerkrankungen gewinnt an Fahrt | ||
| MERCK KGAA | 131,80 | -2,08 % | JEFFERIES stuft MERCK KGAA auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Merck KGaA mit einem Kursziel von 144 Euro auf "Hold" belassen. Nach jüngst dem Life-Science-Bereich widmete sich James... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,900 | 0,00 % | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | ||
| NOVO NORDISK | 38,770 | -0,51 % | DEUTSCHE BANK RESEARCH stuft NOVO NORDISK auf 'Sell' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novo Nordisk mit einem Kursziel von 265 dänischen Kronen auf "Sell" belassen. Dies schrieb Emmanuel Papadakis in seinem am... ► Artikel lesen | |
| APNIMED | 28,790 | 0,00 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 59,42 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| NOVARTIS | 118,20 | -0,47 % | DEUTSCHE BANK RESEARCH stuft NOVARTIS AG auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis mit einem Kursziel von 140 Franken auf "Buy" belassen. Die Studiendaten von Remibrutinib bei schubförmiger Multipler... ► Artikel lesen | |
| KARDIGAN | 21,600 | 0,00 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,215 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| LB PHARMACEUTICALS | 49,360 | 0,00 % | LB Pharmaceuticals Appoints Joseph Miller As Chief Financial Officer | ||
| OMNIAB | 4,240 | 0,00 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen |